pipette
ENEnglish

Genetic Architecture of Plasma Amyloid and Tau Biomarkers in the Amish

P. Wang, D. Z. Jian, Y. E. Song, A. Lynn, K. Miskimen, P. G. Whitehead, A. V. Gulyayev, M. B. Prough, D. A. Dorfsman, R. A. Laux, S. L. Fuzzell, D. Miller, S. D. Hochstetler, P. Miron, A. F. Zaman, L. D. Adams, L. J. Caywood, J. E. Clouse, S. D. Herington, Y. Liu, N. C. Moore, P. Ogrocki, A. J. Lerner, A. J. Griswold, M. L. Cuccaro, J. M. Vance, W. K. Scott, M. A. Pericak-Vance, J. L. Haines

Preprint

En palabras de los autores

Background: Plasma biomarkers offer a minimally invasive alternative for detecting Alzheimer disease (AD) pathology, yet the genetic determinants influencing their levels remain largely underexplored. Objective: To identify genetic variants associated with AD-related plasma biomarker levels in a Midwestern Amish cohort. Methods: We analyzed plasma levels of amyloid beta (A{beta}42/A{beta}40), phosphorylated tau 181 (p-tau181), and the p-tau181/A{beta}42 ratio in the Midwestern Amish. Genome-wide association studies (GWAS) were used to examine associations with common genetic variants, while genetic linkage analysis was used to assess the potential impact of rare variants. Results: GWAS found associations between plasma biomarkers and the APOE gene. Additionally, novel candidate genes were implicated, including MME for A{beta}42/A{beta}40 ratio, and VEGFC and LRRTM4 for p-tau181. Linkage analysis identified significant signals for p-tau181 on chromosome 1, potentially involving the CSF1 and AHCYL1genes. Conclusions: The novel genetic variants associated with AD pathology implicate metabolic, synaptic, neuronal, and immune pathways. The use of GWAS and linkage analysis sheds light on the genetic architecture of AD-related plasma biomarkers.

Resultado principalEl resumen no menciona limitaciones.

Apareció: martes, 20 de octubre. medRxiv. Preprint, todavía sin revisión por pares.

DOI: 10.64898/2026.10.15.26365636